---

The Cancer Research Program (CRP) benefits from new state-of-the-art facilities to conduct basic research at the Centre for Translational Biology, clinical cancer research at the Centre for Innovative Medicine, and evaluative cancer research at the Centre for Outcomes Research and Evaluation. Activities are supported by several newly enhanced technology platforms at the Glen site, including the Immunophenotyping, Histopathology, Biobank, Proteomics, Microscopy, Molecular Imaging, Small Animal Imaging Labs and Drug Discovery platforms.

The integration of basic, clinical and evaluative science has resulted in a new program that is able to pursue precision care research in collaboration with the Cedars Cancer Centre of the MUHC at the Glen. The CRP focuses on the mechanisms of etiology (hereditary predisposition), spread (metastasis) and progression of disease, with current studies in such domains as the identification of new markers and therapeutic targets, gene therapy, tumour suppressor genes, angiogenesis and radiosensitivity.

Program leader: Peter Metrakos, MD
Associate leader: Patricia Tonin, PhD
Manager: Marie-Claude Gingras, PhD